Avidity Biosciences, Inc.
NASDAQ:RNA
41.71 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 9.56 | 9.224 | 9.326 | 6.787 | 2.319 | 0.379 |
| Cost of Revenue
| 2.101 | 1.387 | 0.639 | 37.602 | 14.539 | 8.436 |
| Gross Profit
| 7.459 | 7.837 | 8.687 | -30.815 | -12.22 | -8.057 |
| Gross Profit Ratio
| 0.78 | 0.85 | 0.931 | -4.54 | -5.27 | -21.259 |
| Reseach & Development Expenses
| 190.968 | 150.404 | 101.182 | 37.602 | 14.539 | 8.436 |
| General & Administrative Expenses
| 54.19 | 37.733 | 26.195 | 13.462 | 5.112 | 2.441 |
| Selling & Marketing Expenses
| -2.101 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 52.089 | 37.733 | 26.195 | 13.462 | 5.112 | 2.441 |
| Other Expenses
| -0.594 | 4.918 | 0.042 | -0.078 | 0 | 0 |
| Operating Expenses
| 243.057 | 188.137 | 127.377 | 51.064 | 19.651 | 10.877 |
| Operating Income
| -235.598 | -178.913 | -118.051 | -44.277 | -17.332 | -10.498 |
| Operating Income Ratio
| -24.644 | -19.396 | -12.658 | -6.524 | -7.474 | -27.699 |
| Total Other Income Expenses Net
| 23.378 | 4.918 | 0.042 | -0.078 | -7.402 | -0.718 |
| Income Before Tax
| -212.22 | -173.995 | -118.009 | -44.355 | -24.734 | -11.216 |
| Income Before Tax Ratio
| -22.199 | -18.863 | -12.654 | -6.535 | -10.666 | -29.594 |
| Income Tax Expense
| 1.933 | -4.918 | -0.639 | -0.373 | 7.387 | 0.718 |
| Net Income
| -212.22 | -169.077 | -117.37 | -43.982 | -32.121 | -11.934 |
| Net Income Ratio
| -22.199 | -18.33 | -12.585 | -6.48 | -13.851 | -31.488 |
| EPS
| -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EPS Diluted
| -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EBITDA
| -233.497 | -178.913 | -118.051 | -44.277 | -16.984 | -10.115 |
| EBITDA Ratio
| -24.424 | -19.396 | -12.658 | -6.524 | -7.324 | -26.689 |